Micafungin + fluconazole
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Invasive Candidiasis
Conditions
Invasive Candidiasis, Candidemia
Trial Timeline
Aug 1, 2004 โ Jul 1, 2006
NCT ID
NCT00189709About Micafungin + fluconazole
Micafungin + fluconazole is a phase 3 stage product being developed by Astellas Pharma for Invasive Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00189709. Target conditions include Invasive Candidiasis, Candidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189709 | Phase 3 | Completed |
| NCT00666185 | Phase 3 | Completed |
Competing Products
20 competing products in Invasive Candidiasis